Association of remnant cholesterol with renal function and its progression in patients with type 2 diabetes related chronic kidney disease

被引:4
作者
Li, Qiuhong [1 ,2 ,3 ]
Wang, Tongdan [1 ,2 ,3 ]
Shao, Xian [1 ,2 ,3 ]
Fan, Xiaoguang [4 ]
Lin, Yao [1 ,2 ,3 ]
Cui, Zhuang [5 ]
Liu, Hongyan [1 ,2 ,3 ]
Zhou, Saijun [1 ,2 ,3 ]
Yu, Pei [1 ,2 ,3 ]
机构
[1] Tianjin Med Univ, Chu Hsien I Mem Hosp, NHC Key Lab Hormones & Dev, Tianjin, Peoples R China
[2] Tianjin Med Univ, Tianjin Inst Endocrinol, Tianjin, Peoples R China
[3] Tianjin Med Univ, Tianjin Key Lab Metab Dis, Tianjin, Peoples R China
[4] Fuwai Cent China Cardiovasc Hosp, Dept Nephrol, Zhengzhou, Henan, Peoples R China
[5] Tianjin Med Univ, Dept Epidemiol & Hlth Stat, Tianjin, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词
remnant cholesterol; renal function; renal function progression; type; 2; diabetes; chronic kidney disease; HIGH-DENSITY-LIPOPROTEIN; LDL CHOLESTEROL; CARDIOVASCULAR-DISEASE; RISK; HDL; TRIGLYCERIDES; CELLS; DYSLIPIDEMIA; PROTEINURIA; SUPEROXIDE;
D O I
10.3389/fendo.2024.1331603
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The association of Remnant cholesterol (RC) with renal function and its progression in patients with Type 2 diabetes (T2DM) related chronic kidney disease (CKD) remains unclear. Methods 8,678 patients with T2DM-related CKD were included in cross-sectional analysis, and 6,165 patients were enrolled in longitudinal analysis and followed up for a median of 36.0 months. The outcomes were renal composite endpoint event and rapid progression of renal function. Results 24.54% developed a renal composite endpoint event, and 27.64% rapid progression of renal function. RC levels above 0.56 mmol/L independently increased the risk of both renal composite endpoint (HR, 1.17; 95% CIs, 1.03-1.33) and rapid progression of renal function (OR, 1.17; 95% CIs, 1.01- 1.37). TG levels above 1.65 mmol/L only increased the risk of renal composite endpoint (HR, 1.16; 95% CIs, 1.02 -1.32). TC levels above 5.21 mmol/L increased the risk of renal composite endpoint (HR, 1.14; 95% CIs, 1.01-1.29) only in patients with proteinuria >= 0.5g/d. Conversely, HDL-C levels below 1.20 mmol/L or above 1.84 mmol/L increased the risk of rapid progression of renal function (OR, 0.88; 95% CIs, 0.70 -0.99) in patients with proteinuria<0.5g/d (all P<0.05). Conclusion In patients with T2DM-related CKD, RC was an independent risk factor for progression of renal function, and maintaining it below 0.56 mmol/L could reduce the risk of renal function progression.
引用
收藏
页数:11
相关论文
共 50 条
[1]   How does proteinuria cause progressive renal damage? [J].
Abbate, Mauro ;
Zoja, Carla ;
Remuzzi, Giuseppe .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (11) :2974-2984
[2]   Diabetic Kidney Disease Challenges, Progress, and Possibilities [J].
Alicic, Radica Z. ;
Rooney, Michele T. ;
Tuttle, Katherine R. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (12) :2032-2045
[3]   LpA-1, LpA-I:A-II HDL and CHD-risk:: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial [J].
Asztalos, Bela F. ;
Demissie, Serkalem ;
Cupples, L. Adrienne ;
Collins, Dorothea ;
Cox, Caitlin E. ;
Horvath, Katalin V. ;
Bloomfield, Hanna E. ;
Robins, Sander J. ;
Schaefer, Ernst J. .
ATHEROSCLEROSIS, 2006, 188 (01) :59-67
[4]   An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients [J].
Bermudez-Lopez, Marcelino ;
Forne, Caries ;
Amigo, Nuria ;
Bozic, Milica ;
Arroyo, David ;
Bretones, Teresa ;
Alonso, Nuria ;
Cambray, Serafi ;
Dolores Del Pino, Maria ;
Mauricio, Didac ;
Luis Gorriz, Jose ;
Fernandez, Elvira ;
Manuel Valdivielso, Jose .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (07) :619-630
[5]   Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J].
Bikbov, Boris ;
Purcell, Carrie ;
Levey, Andrew S. ;
Smith, Mari ;
Abdoli, Amir ;
Abebe, Molla ;
Adebayo, Oladimeji M. ;
Afarideh, Mohsen ;
Agarwal, Sanjay Kumar ;
Agudelo-Botero, Marcela ;
Ahmadian, Elham ;
Al-Aly, Ziyad ;
Alipour, Vahid ;
Almasi-Hashiani, Amir ;
Al-Raddadi, Rajaa M. ;
Alvis-Guzman, Nelson ;
Amini, Saeed ;
Andrei, Tudorel ;
Andrei, Catalina Liliana ;
Andualem, Zewudu ;
Anjomshoa, Mina ;
Arabloo, Jalal ;
Ashagre, Alebachew Fasil ;
Asmelash, Daniel ;
Ataro, Zerihun ;
Atout, Maha Moh'd Wahbi ;
Ayanore, Martin Amogre ;
Badawi, Alaa ;
Bakhtiari, Ahad ;
Ballew, Shoshana H. ;
Balouchi, Abbas ;
Banach, Maciej ;
Barquera, Simon ;
Basu, Sanjay ;
Bayih, Mulat Tirfie ;
Bedi, Neeraj ;
Bello, Aminu K. ;
Bensenor, Isabela M. ;
Bijani, Ali ;
Boloor, Archith ;
Borzi, Antonio M. ;
Camera, Luis Alberto ;
Carrero, Juan J. ;
Carvalho, Felix ;
Castro, Franz ;
Catala-Lopez, Ferran ;
Chang, Alex R. ;
Chin, Ken Lee ;
Chung, Sheng-Chia ;
Cirillo, Massimo .
LANCET, 2020, 395 (10225) :709-733
[6]   Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression [J].
Bowe, Benjamin ;
Xie, Yan ;
Xian, Hong ;
Balasubramanian, Sumitra ;
Al-Aly, Ziyad .
KIDNEY INTERNATIONAL, 2016, 89 (04) :886-896
[7]   Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease [J].
Castaner, Olga ;
Pinto, Xavier ;
Subirana, Isaac ;
Amor, Antonio J. ;
Ros, Emilio ;
Hernaez, Alvaro ;
Angel Martinez-Gonzalez, Miguel ;
Corella, Dolores ;
Salas-Salvado, Jordi ;
Estruch, Ramon ;
Lapetra, Jose ;
Gomez-Gracia, Enrique ;
Alonso-Gomez, Angel M. ;
Fiol, Miquel ;
Serra-Majem, Lluis ;
Corbella, Emili ;
Benaiges, David ;
Sorli, Jose V. ;
Ruiz-Canela, Miguel ;
Babio, Nancy ;
Sierra, Lucas Tojal ;
Ortega, Emilio ;
Fito, Montserrat .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (23) :2712-2724
[8]   Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III [J].
Chan, Doris T. ;
Dogra, Gursharan K. ;
Irish, Ashley B. ;
Ooi, Esther M. ;
Barrett, P. Hugh ;
Chan, Dick C. ;
Watts, Gerald F. .
JOURNAL OF LIPID RESEARCH, 2009, 50 (12) :2524-2531
[9]   Hyperlipidemia and Long-Term Outcomes in Nondiabetic Chronic Kidney Disease [J].
Chawla, Varun ;
Greene, Tom ;
Beck, Gerald J. ;
Kusek, John W. ;
Collins, Allan J. ;
Sarnak, Mark J. ;
Menon, Vandana .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (09) :1582-1587
[10]   Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose [J].
Chen, HC ;
Guh, JY ;
Shin, SJ ;
Lai, YH .
ATHEROSCLEROSIS, 2002, 160 (01) :141-146